The 2-Minute Rule for ABBV-744 and other BRD4 inhibitors comparison
In Segment C, contributors will get ABBV-744 and oral navitoclax. In Phase D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment right until ailment progression or the individuals are unable to tolerate the study drugs.There may be better treatment burden for members On this trial when compared with their standard of care